Tisdag 13 Maj | 13:10:03 Europe / Stockholm

Bifogade filer

Kalender

Est. tid*
2026-02-11 10:30 Bokslutskommuniké 2025
2025-11-12 08:30 Kvartalsrapport 2025-Q3
2025-08-27 08:30 Kvartalsrapport 2025-Q2
2025-05-30 N/A X-dag ordinarie utdelning QLIFE 0.00 SEK
2025-05-28 N/A Årsstämma
2025-05-20 08:30 Kvartalsrapport 2025-Q1
2025-03-21 - Extra Bolagsstämma 2025
2025-02-12 - Bokslutskommuniké 2024
2024-11-07 - Kvartalsrapport 2024-Q3
2024-08-29 - Kvartalsrapport 2024-Q2
2024-07-30 - Split QLIFE 2000:1
2024-05-28 - Kvartalsrapport 2024-Q1
2024-05-08 - X-dag ordinarie utdelning QLIFE 0.00 SEK
2024-05-07 - Årsstämma
2024-02-08 - Bokslutskommuniké 2023
2024-01-16 - Extra Bolagsstämma 2023
2023-11-13 - Kvartalsrapport 2023-Q3
2023-08-17 - Kvartalsrapport 2023-Q2
2023-05-26 - Kvartalsrapport 2023-Q1
2023-05-05 - X-dag ordinarie utdelning QLIFE 0.00 SEK
2023-05-04 - Årsstämma
2023-03-24 - Extra Bolagsstämma 2022
2023-02-16 - Bokslutskommuniké 2022
2022-11-25 - Kvartalsrapport 2022-Q3
2022-08-29 - Kvartalsrapport 2022-Q2
2022-05-06 - X-dag ordinarie utdelning QLIFE 0.00 SEK
2022-05-05 - Årsstämma
2022-05-05 - Kvartalsrapport 2022-Q1
2022-02-17 - Bokslutskommuniké 2021
2021-11-08 - Kvartalsrapport 2021-Q3
2021-08-16 - Kvartalsrapport 2021-Q2
2021-05-06 - X-dag ordinarie utdelning QLIFE 0.00 SEK
2021-05-05 - Årsstämma
2021-05-05 - Kvartalsrapport 2021-Q1
2021-02-18 - Bokslutskommuniké 2020
2020-11-19 - Extra Bolagsstämma 2020
2020-11-18 - Kvartalsrapport 2020-Q3
2020-08-18 - Kvartalsrapport 2020-Q2
2020-05-22 - X-dag ordinarie utdelning QLIFE 0.00 SEK
2020-05-20 - Årsstämma
2020-05-20 - Kvartalsrapport 2020-Q1

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Qlife Holding är verksamt inom medicinteknik. Bolaget är specialiserat inom forskning och utveckling av IVD-enheter. Enheterna används som biomarkörstester i blod och används som komplement till övriga tester inom vården. Samarbete utförs även med övriga aktörer på marknaden. Störst verksamhet återfinns inom den nordiska marknaden, med huvudkontoret i Helsingborg.
2022-02-17 09:30:00

Ninety percent full year sales growth

FINANCIAL SUMMARY - FOURTH QUARTER 2021
  • Revenue in the period amounted to kSEK 12,084 (9,122). Revenue regards sales of Egoo.Health devices and COVID-19 test capsules.
  • EBITDA for the period amounted to kSEK -11,850 (-6,501), and net loss kSEK -15,805 (-7,602).
  • The total cash flow in the fourth quarter amounted to kSEK -9,307 (-1,013).
  • Earnings per share before/after dilution for the fourth quarter amounted to SEK -1.02 (-0.68), calculated on weighted average number of shares in the period.
 FINANCIAL SUMMARY - JANUARY -DECEMBER 2021
  • Revenue in the period amounted to kSEK 39,613 (20,750). Revenue includes sales of COVID-19 tests from the test service center as well as Egoo.Health devices and capsules for decentralized testing.

  • EBITDA for the period amounted to kSEK -35,383 (-19,422), and net loss kSEK -48,838 (-20,200).

  • In the second quarter, Qlife raised MSEK 121.2 (after issuance costs) through a directed share issue and the exercise of TO1 warrants.

  • The total cash flow for the full year amounted to kSEK 52,600 (15,253).
  • Shareholders equity as of 31 December amounted to kSEK 163,179 (89,549).
  • Earnings per share before/after dilution for the year amounted to SEK -3.83 (-1.91).
SIGNIFICANT EVENTS - FOURTH QUARTER 2021
  • Qlife signed an agreement with FIND, the global alliance for diagnostics, for a funding of MUSD 3.45 for a 12-month project to develop a novel two-in-one assay for the detection of influenza and SARS-CoV-2 viruses in decentralized healthcare settings. In December, the first installment was paid out to Qlife from FIND, amounting to MSEK 12.
  • In November, the scientific study of the company's COVID-19 on the Egoo platform test was accepted and subsequently published in Natures Scientific Reports. (https://www.nature.com/srep/).
  • Qlife recruited Kasper Damgaard Rousøe as new Chief Financial Officer (CFO) for Qlife Holding AB and subsidiary Qlife Aps. Kasper will join Qlife as per 1 March.
  • In accordance with the decision at Qlife Holding's Annual General assembly a Nomination committee was convened, consisting of: Anita Otterheim Hjalmarsson, Sören Skjärbäk, Lars Bangsgaard and Mette Gross.

Link to report: https://qlifeholding.com/sv/investerare/finansiella-rapporter

This disclosure contains information that Qlife Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 17-02-2022 09:30 CET.